Latest news with #Welldoc
Yahoo
04-06-2025
- Business
- Yahoo
Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies
Providing Cardiometabolic Digital Health Support for Patients prescribed Zepbound® (tirzepatide) or Mounjaro® (tirzepatide) COLUMBIA, Md., June 04, 2025--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lilly Health app) with its cardiometabolic digital health platform. The Lilly Health app is designed to support a tailored patient experience for individuals interested in or using Eli Lilly and Company's incretin-based therapies, for the treatment of cardiometabolic conditions, such as obesity, type 2 diabetes and moderate- to-severe obstructive sleep apnea and obesity. Initially, the Lilly Health app will be available for patients prescribed Zepbound® (tirzepatide)** or Mounjaro® (tirzepatide)**. Lilly and Welldoc aim to build a more seamless patient experience through educational resources and targeted support. The Lilly Health app will provide features to help patients with their cardiometabolic health goals and weight, such as medication logging, reminders, device connectivity and health data tracking. "We are incredibly proud to expand our impactful work with Lilly. Welldoc's robust and AI-powered digital health platform is uniquely equipped to be a powerful foundation for the Lilly Health app," said Kevin McRaith, President and CEO of Welldoc. "Our proven ability to integrate complex data, deliver personalized insights and support individuals across multiple cardiometabolic conditions positions us as the ideal technology partner for Lilly's ambitious vision. We are confident that our scalable and secure platform will enable Lilly Health to deliver a truly transformative and connected experience for patients." The Lilly Health app is built upon Welldoc's well-established digital cardiometabolic platform, which provides individuals with extensive device and data connectivity, in-app nutrition and exercise resources, and comprehensive trends and insights to help individuals manage complex cardiometabolic conditions with their providers and optimize their overall health over time. About Welldoc Welldoc®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50+ patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, The Wall Street Journal and The Economist. The company has been named the "Best Overall Digital Health Company" by MedTech Breakthrough for the past two years and was selected as a winner of the 2025 AI Excellence Awards by Business Intelligence Group, 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit Follow us on LinkedIn and X. *Lilly Health™ Personalized Health & Medicine Platform Lilly Health Personalized Health & Medicine Platform is intended for use as a health management aid for adult patients 18 years or older who have been prescribed Zepbound® (tirzepatide) or Mounjaro® (tirzepatide). Lilly Health provides Zepbound and Mounjaro users with medication reminders, medication dose logging, and health data logging. Lilly Health is not intended to provide treatment decisions or replace the care and advice of a licensed Health Care Provider (HCP). All medical analysis and treatment plans should be performed by a licensed HCP. ** Zepbound® (tirzepatide) Zepbound is an injectable prescription medicine that may help adults with: obesity, or some adults with overweight who has have weight-related medical problems to lose excess body weight and keep the weight off moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. See for full indications of use. **Mounjaro® (tirzepatide) Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age. See for full indications of use. View source version on Contacts Sylvia ArandaReal Chemistrysaranda@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
04-06-2025
- Business
- Business Wire
Welldoc Works with Lilly to Launch a New Personalized Health & Medicine Platform for Those Prescribed Lilly's Incretin Therapies
COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Health™ Personalized Health & Medicine Platform* (Lilly Health app) with its cardiometabolic digital health platform. The Lilly Health app is designed to support a tailored patient experience for individuals interested in or using Eli Lilly and Company's incretin-based therapies, for the treatment of cardiometabolic conditions, such as obesity, type 2 diabetes and moderate- to-severe obstructive sleep apnea and obesity. Initially, the Lilly Health app will be available for patients prescribed Zepbound® (tirzepatide)** or Mounjaro® (tirzepatide)**. Lilly and Welldoc aim to build a more seamless patient experience through educational resources and targeted support. The Lilly Health app will provide features to help patients with their cardiometabolic health goals and weight, such as medication logging, reminders, device connectivity and health data tracking. "We are incredibly proud to expand our impactful work with Lilly. Welldoc's robust and AI-powered digital health platform is uniquely equipped to be a powerful foundation for the Lilly Health app,' said Kevin McRaith, President and CEO of Welldoc. 'Our proven ability to integrate complex data, deliver personalized insights and support individuals across multiple cardiometabolic conditions positions us as the ideal technology partner for Lilly's ambitious vision. We are confident that our scalable and secure platform will enable Lilly Health to deliver a truly transformative and connected experience for patients.' The Lilly Health app is built upon Welldoc's well-established digital cardiometabolic platform, which provides individuals with extensive device and data connectivity, in-app nutrition and exercise resources, and comprehensive trends and insights to help individuals manage complex cardiometabolic conditions with their providers and optimize their overall health over time. About Welldoc Welldoc ®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50+ patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, The Wall Street Journal and The Economist. The company has been named the 'Best Overall Digital Health Company' by MedTech Breakthrough for the past two years and was selected as a winner of the 2025 AI Excellence Awards by Business Intelligence Group, 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit Follow us on LinkedIn and X. *Lilly Health™ Personalized Health & Medicine Platform Lilly Health Personalized Health & Medicine Platform is intended for use as a health management aid for adult patients 18 years or older who have been prescribed Zepbound® (tirzepatide) or Mounjaro® (tirzepatide). Lilly Health provides Zepbound and Mounjaro users with medication reminders, medication dose logging, and health data logging. Lilly Health is not intended to provide treatment decisions or replace the care and advice of a licensed Health Care Provider (HCP). All medical analysis and treatment plans should be performed by a licensed HCP. ** Zepbound® (tirzepatide) Zepbound is an injectable prescription medicine that may help adults with: obesity, or some adults with overweight who has have weight-related medical problems to lose excess body weight and keep the weight off moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. It should be used with a reduced-calorie diet and increased physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. See for full indications of use. **Mounjaro® (tirzepatide) Mounjaro is an injectable prescription medicine that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes mellitus. It is not known if Mounjaro can be used in people who have had pancreatitis. Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age. See for full indications of use.
Yahoo
08-05-2025
- Business
- Yahoo
Welldoc Named "Best Overall Digital Health Company" for Third Consecutive Year in 9th Annual MedTech Breakthrough Awards Program
COLUMBIA, Md., May 08, 2025--(BUSINESS WIRE)--Welldoc®, a digital health leader revolutionizing AI-driven cardiometabolic care, today announced that it has been selected as winner of the "Best Overall Digital Health Company" award for the third consecutive year in the MedTech Breakthrough Awards. The annual awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market. This is the fourth year that MedTech Breakthrough has recognized Welldoc for its leadership and innovation in the digital health industry. Welldoc's comprehensive AI-driven platform delivers flexible, multi-condition digital coaching across diabetes, hypertension, heart failure, prediabetes and weight management, including GLP-1 support. The company enables health plans, health systems and employers to extend traditional care models and partners with pharmaceutical and medical device industry leaders to develop first-in-class, regulated combination products. Welldoc's leadership is grounded in clinical rigor and regulatory expertise, as demonstrated by over 90 clinical publications, 11 FDA 510(k) clearances for diabetes functionality, and 54 novel patents for their first-in-class AI technology. The company's AI correlates insights across a broad spectrum of health data, and its dynamic, adaptive models offer actionable predictive capabilities to support improved health outcomes across multiple conditions. "Precise personalization is not the future – it's the present, and Welldoc meets this need with our digital-first solutions focused on whole-person health. By proactively anticipating evolving AI guidelines, we are driving innovation and ensuring safety, accuracy and adaptability in this rapidly evolving field," said Kevin McRaith, President and CEO of Welldoc. "Thank you to MedTech Breakthrough for recognizing our commitment to innovation and achievement in this space." The MedTech Breakthrough Awards program celebrates excellence, innovation and meaningful progress in a wide range of categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy and more. This year's program attracted nominations from more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry. "Welldoc delivers a tailored solution for unique needs, no matter where an individual is on their journey. At every step, Welldoc provides users with an effortless, intuitive and engaging user experience. With personalized insights at their fingertips, individuals are better equipped to manage their health independently – enabling improved long-term outcomes," said Steve Johansson, Managing Director of MedTech Breakthrough. "Welldoc is the clear choice for 2025's 'Best Overall Digital Health Company.'" About Welldoc Welldoc®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50 patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, the Wall Street Journal and the Economist. The company has been named the "Best Overall Digital Health Company" by MedTech Breakthrough for the past three years, and was selected as a winner of the 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit Follow us on LinkedIn and X. About MedTech Breakthrough Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose. View source version on Contacts CTD CommsMegan Prock McGrath573-578-1184megan@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
08-05-2025
- Business
- Business Wire
Welldoc Named 'Best Overall Digital Health Company' for Third Consecutive Year in 9 th Annual MedTech Breakthrough Awards Program
BUSINESS WIRE)-- Welldoc ®, a digital health leader revolutionizing AI-driven cardiometabolic care, today announced that it has been selected as winner of the 'Best Overall Digital Health Company' award for the third consecutive year in the MedTech Breakthrough Awards. The annual awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market. This is the fourth year that MedTech Breakthrough has recognized Welldoc for its leadership and innovation in the digital health industry. Welldoc's comprehensive AI-driven platform delivers flexible, multi-condition digital coaching across diabetes, hypertension, heart failure, prediabetes and weight management, including GLP-1 support. The company enables health plans, health systems and employers to extend traditional care models and partners with pharmaceutical and medical device industry leaders to develop first-in-class, regulated combination products. Welldoc's leadership is grounded in clinical rigor and regulatory expertise, as demonstrated by over 90 clinical publications, 11 FDA 510(k) clearances for diabetes functionality, and 54 novel patents for their first-in-class AI technology. The company's AI correlates insights across a broad spectrum of health data, and its dynamic, adaptive models offer actionable predictive capabilities to support improved health outcomes across multiple conditions. 'Precise personalization is not the future – it's the present, and Welldoc meets this need with our digital-first solutions focused on whole-person health. By proactively anticipating evolving AI guidelines, we are driving innovation and ensuring safety, accuracy and adaptability in this rapidly evolving field,' said Kevin McRaith, President and CEO of Welldoc. 'Thank you to MedTech Breakthrough for recognizing our commitment to innovation and achievement in this space.' The MedTech Breakthrough Awards program celebrates excellence, innovation and meaningful progress in a wide range of categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy and more. This year's program attracted nominations from more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry. 'Welldoc delivers a tailored solution for unique needs, no matter where an individual is on their journey. At every step, Welldoc provides users with an effortless, intuitive and engaging user experience. With personalized insights at their fingertips, individuals are better equipped to manage their health independently – enabling improved long-term outcomes,' said Steve Johansson, Managing Director of MedTech Breakthrough. 'Welldoc is the clear choice for 2025's 'Best Overall Digital Health Company.'' About Welldoc Welldoc®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50 patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, the Wall Street Journal and the Economist. The company has been named the 'Best Overall Digital Health Company' by MedTech Breakthrough for the past three years, and was selected as a winner of the 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit Follow us on LinkedIn and X. About MedTech Breakthrough Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Yahoo
23-04-2025
- Business
- Yahoo
Welldoc Certified as a Great Place to Work® for Fourth Consecutive Year
COLUMBIA, Md., April 23, 2025--(BUSINESS WIRE)--Welldoc®, a digital health leader revolutionizing cardiometabolic care, announced today that it was Certified™ by Great Place to Work® for the fourth year in a row. This prestigious award recognizes companies with exceptional workplace cultures based solely on employee feedback. An impressive 94 percent of employees said Welldoc is a great place to work, exceeding the U.S. average by 37 points. Great Place to Work is the global authority on workplace culture, employee experience and leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation. The Great Place to Work Certification is based on results of the Trust Index™ survey administered by the Great Place to Work Institute, which assesses employee satisfaction in key areas, including credibility, respect, fairness and camaraderie. "At Welldoc, we firmly believe that our people are our greatest asset as we work to advance better cardiometabolic health," said Kevin McRaith, President and CEO of Welldoc. "This fourth Great Place to Work recognition validates our ongoing investment in growing our talent and creating an environment where individuals can learn, develop and make a meaningful impact on this critical health challenge." The Great Place to Work Certification affirms Welldoc's workplace culture, built upon the company's mission to integrate personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions. Welldoc continues to be recognized for its leadership and innovation, most recently as winner of the 2025 Artificial Intelligence Excellence Award and Innovation Award presented by Business Intelligence Group. "We are intentional about fostering a workplace where innovation thrives and our employees feel valued and empowered to advance our mission," affirmed Robin Schwartz, Head of HR at Welldoc. "We offer comprehensive benefits, and a culture that champions continuous growth and celebrates wins through peer recognition and awards programs, ensuring everyone feels connected to Welldoc's success." We're Hiring!Looking to grow your career at a company that puts its people first? Visit our careers page at: About WelldocWelldoc®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50+ patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, The Wall Street Journal and The Economist. The company has been named the "Best Overall Digital Health Company" by MedTech Breakthrough for the past two years and was selected as a winner of the 2025 AI Excellence Awards by Business Intelligence Group, 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit Follow us on LinkedIn and Twitter. About Great Place to Work Certification™Great Place to Work® Certification™ is the most definitive "employer-of-choice" recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place to Work-Certified. About Great Place to Work® As the global authority on workplace culture, Great Place to Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place to Work Certified™ or receiving recognition on a coveted Best Workplaces™ List. Learn more at and on LinkedIn, Twitter, Facebook and Instagram. View source version on Contacts CTD CommsMegan Prock McGrath573-578-1184megan@
